Trial Profile
Effect of Rizatriptan on Rotational Motion Sickness in Migraineurs.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Rizatriptan (Primary)
- Indications Motion sickness
- Focus Therapeutic Use
- 07 Dec 2014 Protocol has been amended to change in treatment arms from 1 to 4.
- 07 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 30 Dec 2009 New trial record